Strontium ranelate a strontium(II) salt of ranelic acid is a medication for osteoporosis marketed as Protelos or Protos by Servier. On 13 May 2013 Servier released a Direct Healthcare Professional Communication which stated that important new restrictions for the use of Protelos are now in place as randomised trials have shown an increased risk of myocardial infarction.
This page contains content from the copyrighted Wikipedia article "Strontium ranelate"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
